MedTrace Logo

Phase 1 Study of CM082 in Patients With wAMD

NCT02452385 · Status: SUSPENDED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2020-01-13

No results posted yet for this study

Summary

This is a Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CM082 tablets in Chinese Patients With wAMD.

Conditions

  • Age-Related Macular Degeneration

Interventions

DRUG

CM082 tablet

CM082 tablets taken orally

Sponsors & Collaborators

  • West China Hospital

    collaborator OTHER

  • AnewPharma

    lead INDUSTRY

Principal Investigators

  • Ming Zhang, MD · West China Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2020-06-30
Completion
2020-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02452385 on ClinicalTrials.gov